KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China
- 51 Downloads
Natural killer (NK) cells are lymphocytes that play important roles in the host defense against hepatitis C virus (HCV) infection. Killer cell immunoglobulin-like receptors (KIRs) are a group of regulatory molecules expressed on NK cells and a subset of T cells (Parham 2005). Ligands for KIRs are human leukocyte antigen (HLA) class I molecules, and HLA-C1 is a ligand for the inhibitory receptors KIR2DL2, KIR2DL3 and the activating receptor KIR2DS2 (Robinson et al.2003; Du et al.2007). In 2002, the National Institutes of Health Consensus Development Conference concluded that a combination therapy of pegylated alpha interferon (PEG-IFN) with ribavirin (RBV) manages HCV infections effectively (Gebo and Bartlett 2002). Before the direct-acting antiviral agent treatment was approved, PEG-IFN and RBV were the main antiviral treatments for chronic HCV in China (Chinese Society of Hepatology et al.2015). Patients that receive the same standard combination therapies are classified...
We thank all subjects who donated samples for this study. This work was supported by Grants from the National Major Science and Technology Project for Infectious Diseases of China (2012ZX10004503), and Major State Basic Research Development Program of China (973 Program; No. 2013CB530505).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflicts of interest.
Animal and Human Rights Statement
This study conformed to the 1975 Declaration of Helsinki guidelines and permission was obtained from the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. Prior to the study, informed consent was obtained from each individual.
- Carneiro VL, Lemaire DC, Bendicho MT, Souza SL, Cavalcante LN, Angelo AL, Freire SM, Mendes CM, Santana N, Lyra LG, Lyra AC (2010) Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders. Liver Int 30:567–573CrossRefPubMedGoogle Scholar
- Chinese Society of Hepatology CMA, Wei L, Chinese Society of Infectious Diseases CMA, Hou JL (2015) The guideline of prevention and treatment for hepatitis C: a 2015 update. Zhonghua Gan Zang Bing Za Zhi 23:906–923Google Scholar
- de Vasconcelos JM, de Jesus Maues Pereira Moia L, Amaral IS, Miranda EC, Cicalisetakeshita LY, de Oliveira LF, de Araujo Melo Mendes L, Sastre D, Tamegao-Lopes BP, de Aquino Pedroza LS, Batista Dos Santos SE, Soares MC, de Araujo MT, Bandeira CL, de Sousa da Silva AM, de Medeiros ZL, Sena L, Demachki S, Dos Santos EJ (2013) Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis c and responses to therapy in Brazil. Genet Mol Biol 36:22–27CrossRefPubMedPubMedCentralGoogle Scholar
- Gebo KA, Bartlett JG (2002) Management of hepatitis C: a review of the NIH consensus development conference. Hopkins HIV Rep 14:1–4Google Scholar
- Vidal-Castineira JR, Lopez-Vazquez A, Diaz-Pena R, Alonso-Arias R, Martinez-Borra J, Perez R, Fernandez-Suarez J, Melon S, Prieto J, Rodrigo L, Lopez-Larrea C (2010) Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 84:475–481CrossRefPubMedGoogle Scholar
- Vidal-Castineira JR, Lopez-Vazquez A, Martinez-Borra J, Martinez-Camblor P, Prieto J, Lopez-Rodriguez R, Sanz-Cameno P, de la Vega J, Rodrigo L, Perez-Lopez R, Perez-Alvarez R, Lopez-Larrea C (2014) Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome. PLoS ONE 9:e99426CrossRefPubMedPubMedCentralGoogle Scholar
- Zwolinska K, Blachowicz O, Tomczyk T, Knysz B, Gasiorowski J, Zalewska M, Orzechowska BU, Sochocka M, Piasecki E (2016) The effects of killer cell immunoglobulin-like receptor (KIR) genes on susceptibility to HIV-1 infection in the polish population. Immunogenetics 68:327–337CrossRefPubMedPubMedCentralGoogle Scholar